Key result
Irbesartan added to conventional therapy produced favourable trends in exercise tolerance time and LVEF compared with placebo in patients with mild to moderate heart failure.
Why the study?
Does adding irbesartan to conventional therapy including ACE inhibitors improve exercise tolerance time, LVEF, and clinical status in patients with mild to moderate heart failure?
RCT (n=109)
double-blind
randomised
Yes
Does adding irbesartan to conventional therapy including ACE inhibitors improve exercise tolerance time, LVEF, and clinical status in patients with mild to moderate heart failure?
Adding irbesartan to conventional therapy including ACE inhibitors in patients with mild to moderate heart failure produced favorable trends in exercise tolerance and LVEF and was well tolerated.
No takes yet. Share an insight, caveat, or question.
Favorable trends support considering irbesartan add-on in ACEI-treated mild-moderate HF; extends ARB evidence while leaving outcome benefits open.
Tonkon et al. (2000) conducted an RCT in heart failure (n=109). Irbesartan vs. Placebo was evaluated on Exercise tolerance time (ETT), LVEF and clinical status. Irbesartan added to conventional therapy produced favourable trends in exercise tolerance time and LVEF compared with placebo in patients with mild to moderate heart failure.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: